Elbasvir/Grazoprevir

elbasvir/grazoprevir · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Elbasvir/Grazoprevir, covering 2017-11-09 to 2023-02-22. Get the full timeline:

Most recent: Clinical Trial Update: Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients [Phase 3]